TW202319397A - NKp46結合多肽及其用途 - Google Patents

NKp46結合多肽及其用途 Download PDF

Info

Publication number
TW202319397A
TW202319397A TW111132424A TW111132424A TW202319397A TW 202319397 A TW202319397 A TW 202319397A TW 111132424 A TW111132424 A TW 111132424A TW 111132424 A TW111132424 A TW 111132424A TW 202319397 A TW202319397 A TW 202319397A
Authority
TW
Taiwan
Prior art keywords
polypeptide
cancer
nkp46
seq
amino acid
Prior art date
Application number
TW111132424A
Other languages
English (en)
Chinese (zh)
Inventor
約翰 Ｃ 湯門
伯瑞登 Ｐ 艾克曼
羅杰 Ａ 潘迪
威廉 奎葛
佛羅里安 薩梅爾
海瑟 金基德
那嘉 克恩
Original Assignee
美商英伊布里克斯公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商英伊布里克斯公司 filed Critical 美商英伊布里克斯公司
Publication of TW202319397A publication Critical patent/TW202319397A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW111132424A 2021-08-30 2022-08-29 NKp46結合多肽及其用途 TW202319397A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163238429P 2021-08-30 2021-08-30
US63/238,429 2021-08-30

Publications (1)

Publication Number Publication Date
TW202319397A true TW202319397A (zh) 2023-05-16

Family

ID=84047735

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111132424A TW202319397A (zh) 2021-08-30 2022-08-29 NKp46結合多肽及其用途

Country Status (7)

Country Link
US (1) US20250136681A1 (https=)
EP (1) EP4395895A1 (https=)
JP (1) JP2024534838A (https=)
CN (1) CN117940454A (https=)
CA (1) CA3228815A1 (https=)
TW (1) TW202319397A (https=)
WO (1) WO2023034740A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024206329A1 (en) 2023-03-27 2024-10-03 Modernatx, Inc. Nucleic acid molecules encoding bi-specific secreted engagers and uses thereof
CN120025440A (zh) * 2023-11-21 2025-05-23 南京融捷康生物科技有限公司 一种抗Nkp46的单域抗体及其用途
WO2025137555A1 (en) * 2023-12-20 2025-06-26 Omniab, Inc. Polypeptides that bind to nkp46
WO2025168114A1 (en) * 2024-02-09 2025-08-14 Shanghai Epimab Biotherapeutics Co., Ltd. Multifunctional nk cell engager
CN120574323A (zh) * 2024-02-29 2025-09-02 安升（上海）医药科技有限公司 一种抗NKp46的单域抗体及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016207278A1 (en) * 2015-06-23 2016-12-29 Innate Pharma Multispecific nk engager proteins
US20210024631A1 (en) * 2018-03-28 2021-01-28 Orionis Biosciences, Inc. Bi-functional proteins and construction thereof
KR20210113265A (ko) * 2019-01-07 2021-09-15 인히브릭스, 인크. 변형된 il-2 폴리펩타이드를 포함하는 폴리펩타이드 및 이의 용도

Also Published As

Publication number Publication date
JP2024534838A (ja) 2024-09-26
CA3228815A1 (en) 2023-03-09
CN117940454A (zh) 2024-04-26
EP4395895A1 (en) 2024-07-10
US20250136681A1 (en) 2025-05-01
WO2023034740A1 (en) 2023-03-09

Similar Documents

Publication Publication Date Title
TWI874345B (zh) 包含經修飾il-2多肽之多肽及其用途
US12331126B2 (en) OX40-binding polypeptides and uses thereof
US20250320295A1 (en) CD8-Binding Polypeptides and Uses Thereof
US20250136681A1 (en) NKp46-Binding Polypeptides and Uses Thereof
US20250066477A1 (en) Gamma Delta T-Cell-Binding Polypeptides and Uses Thereof
US20240376198A1 (en) NKp46-Targeted Modified IL-2 Polypeptides and Uses Thereof
TW202309102A (zh) 靶向cd8之經修飾il-2多肽及其用途
US20250109203A1 (en) Gamma Delta T-Cell-Targeted Modified IL-2 Polypeptides and Uses Thereof
RU2802070C2 (ru) Ох40-связывающие полипептиды и их применение
TWI918596B (zh) Ox40結合多肽及其用途
CN117980335A (zh) Cd8结合多肽及其用途